Últimas noticias sobre Elicio Therapeutics (NASDAQ:ELTX) Bolsa

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Descubre las acciones que lideran el premercado con sorprendentes subidas y caídas. INNOVATE y más protagonistas hoy.

Las acciones de INNOVATE (VATE) cotizan un 19% más alto; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Elicio Therapeutics Inc

DA Davidson analyst Brent Thielman maintains Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) with a Neutral and raises the price target from $58 to $68.

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Everus Construction Group, Raises Price Target to $68

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and lowers the price target from $190 to $185.

ILMN

Piper Sandler Maintains Overweight on Illumina, Lowers Price Target to $185

<a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf" title="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf">https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf</a>

MIRA

Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

After rising in tandem last year as hedges against currency depreciation, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold are <a href="https://www.benzinga.com/25/05/45410910/bitcoin-considered-digital-gold-while-it-reaches-103k">no longer moving in sync.</a>
What Happened: According to JPMorgan, the two assets have entered a zero-sum phase in 2025, with gains in one increasingly coming at the other's expense, The Block <a href="https://www.theblock.co/post/354496/jpmorgan-bitcoin-more-upside-gold-h2-2025?utm_source=twitter&amp;utm_medium=social">reported</a>.
JPMorgan analysts, led by managing director Nikolaos Panigirtzoglou, noted a reversal in capital flows in recent months. 
From mid-February to mid-April, gold outperformed while Bitcoin lagged. 
But since late April, the trend has flipped: Bitcoin has climbed 18% while gold has dropped nearly 8%. 
Investor flows and futures data support this divergence, with capital leaving gold ETFs and entering Bitcoin funds.
The bank's strategists expect this competitive dynamic between the two assets to persist through the remainder of the year, though they see more potential upside for Bitcoin. 
&#8220;We are biased towards crypto-specific catalysts creating more upside for Bitcoin over gold into the second half of the year,&#8221; the note said.
One major factor behind Bitcoin's rise is increased institutional and public sector adoption. 
Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Metaplanet have continued accumulating Bitcoin aggressively.
Strategy alone has already secured 60% of its $42 billion goal for Bitcoin purchases, targeting completion by 2027.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a>
Why It Matters: U.S. states are also starting to allocate to Bitcoin.
New Hampshire now permits up to 5% of state assets in Bitcoin and gold, and Arizona is establishing a digital asset reserve fueled by staking yields and token airdrops, while pledging to hold taxes steady.
These developments signal growing acceptance of Bitcoin as a strategic reserve asset. 
JPMorgan believes this trend may become more significant if more states follow suit.
At the same time, structural changes in the crypto derivatives market are boosting investor confidence. 
Coinbase's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) acquisition of Deribit, Kraken's purchase of NinjaTrader, and Gemini's expansion into European derivatives licensing are seen as milestones that could usher in greater institutional engagement, particularly as regulatory clarity improves.
Altogether, with gold under pressure and Bitcoin buoyed by sector-specific growth, JPMorgan sees the second half of the year tilting in favor of the leading cryptocurrency.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45438872/want-to-copytrade-the-trump-linked-world-liberty-financial-portfolio-dont-be-so-sure">Want To Copytrade The Trump-Linked World Liberty Financial Portfolio? Don&#8217;t Be So Sure</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

MSTR

Bitcoin Is Starting To Outperform Gold: JPMorgan

Biotech

General

VTVT

vTv Therapeutics Resumes Screening In Phase 3 CATT1 Study Evaluating Cadisegliatin as Adjunctive Therapy for Type 1 Diabetes

Piper Sandler analyst Mark Lear maintains Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) with a Neutral and lowers the price target from $16 to $15.

VTLE

Piper Sandler Maintains Neutral on Vital Energy, Lowers Price Target to $15

RBC Capital analyst Mike Dahl reiterates Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Outperform and maintains $132 price target.

Reiteration

BLDR

RBC Capital Reiterates Outperform on Builders FirstSource, Maintains $132 Price Target

Truist Securities analyst Jordan Levy maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and raises the price target from $49 to $65.

Truist Securities Maintains Overweight on NEXTracker, Raises Price Target to $65

WIIM

EKSO

EKSO stock has given up its prior gain. Ekso Bionics shares were trading higher after the company announced it has been accepted into the NVIDIA Connect Program.

KE Holdings Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares are trading lower premarket on Thursday after the&nbsp;company&nbsp;reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45431161/ke-holdings-inc-announces-first-quarter-2025-unaudited-financial-results" rel="noreferrer noopener">first-quarter FY25 results</a>.
Net revenues rose&nbsp;42.4% year-over-year (Y/Y) to 23.3 billion&nbsp;Chinese Yuan&nbsp;($3.21 billion), beating the consensus of&nbsp;$3.09 billion.
Mobile monthly active users (MAU) averaged 44.5&nbsp;million in the quarter, vs. 47.7 million a year ago quarter.
Gross transaction value (GTV) reached 843.7 billion Chinese Yuan&nbsp;($116.3&nbsp;billion), up&nbsp;34.0% year-over-year.
GTV existing home transactions grew&nbsp;28.1% Y/Y to 580.3 billion Chinese Yuan&nbsp;($80.0&nbsp;billion), while new home transactions increased&nbsp;53.0% Y/Y to 232.2 billion&nbsp;Chinese Yuan&nbsp;($32.0 billion).
Home renovation and furnishing GTV rose&nbsp;22.3% Y/Y to 2.9 billion&nbsp;Chinese Yuan&nbsp;($0.4 billion), and home rental services surged&nbsp;93.8% Y/Y to 5.1 billion&nbsp;Chinese Yuan&nbsp;($0.7 billion).
Gross profit increased by&nbsp;17.0% Y/Y to 4.8 billion&nbsp;Chinese Yuan&nbsp;($0.7 billion).
Gross margin declined to&nbsp;20.7% from&nbsp;25.2% due to a lower proportion of net revenues and lower contribution margin from existing home transaction services.
Adjusted EBITDA rose to 1.84 billion&nbsp;Chinese Yuan&nbsp;($254&nbsp;million) from 1.67 billion Chinese Yuan in the same period last year.
Adjusted earnings per ADS stood at 1.19 Chinese Yuan. In USD, the adjusted EPS of&nbsp;$0.16 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">is in line with the consensus</a>.
As of March 31, 2025, cash, cash equivalents, restricted cash and short-term investments stood at 54.8 billion Chinese Yuan&nbsp;($7.6 billion).
As of March 31, 2025, the number of stores rose to 56,849, an increase of&nbsp;28.6% Y/Y, with active stores up&nbsp;29.6% to 55,210.
Stanley Yongdong Peng, Chairman of the Board and Chief Executive Officer of Beike, said, &#8220;Building on the stable market performance and the continued effectiveness of our growth strategy, our business maintained strong growth in the first quarter, with our total transaction value increasing by 34.0% year-over-year and net revenues rising by 42.4%.&#8221;
&#8221;Our housing transaction services continue to significantly outperform the market. Our platform continually empowers more industry partners, with the numbers of active stores and agents increasing notably by 29.6% and 23.0% year-over-year, respectively, and with improvements in both agent and store efficiency.&#8221;
Mr. Tao Xu, Executive Director and Chief Financial Officer of Beike, added, &#8220;In the first quarter, the market performance was very stable, continuing the positive impact resulting from the policies implemented in September last year. National new home sales remained relatively flat year-over-year in the first quarter, better than the substantial year-over-year decline in the same period last year, and the existing home market remained at a high level in activity.&#8221;
Investors can gain exposure to the stock via&nbsp;Global X PropTech ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEC#NASDAQ">PTEC</a>) and&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>)
Price Action: BEKE shares are down 5.44% at $19.13 premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45322954" target="_blank" rel="noreferrer noopener">Compass Analysts Lower Their Forecasts After Weaker-Than-Expected Results</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

BEKE

PowerShares Golden Dragon Halter USX China Portfolio

PTEC

BEKE's Q1 Revenue Soars 42%, Transaction Value Surges 34% as China's Housing Market Stabilizes

Piper Sandler analyst Frank Schiraldi maintains Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) with a Overweight and raises the price target from $110 to $123.

BPOP

Piper Sandler Maintains Overweight on Popular, Raises Price Target to $123

RBC Capital analyst Kenneth Lee reiterates Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBDC#NYSE">OBDC</a>) with a Outperform and maintains $16 price target.

OBDC

RBC Capital Reiterates Outperform on Blue Owl Capital, Maintains $16 Price Target

Piper Sandler analyst Peter Keith maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $162 to $184.

BOOT

Piper Sandler Maintains Overweight on Boot Barn Holdings, Raises Price Target to $184

<a href="https://www.benzinga.com/25/04/44608617/jp-morgan-hikes-us-recession-odds-to-40-tariffs-create-a-dilemma-for-the-fed">JPMorgan Chase</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has quietly shut down Capital Connect, its startup-venture capital matchmaking platform launched just two years ago. The site went offline in late 2024 without a formal announcement from the bank, and sources familiar with the decision say the platform failed to meet expectations, according to <a href="https://fortune.com/article/jpmorgan-chase-banking-startups-venture-capital-capital-connect-silicon-valley-bank/">Fortune</a>.
Capital Connect was introduced in 2022 as a bold move to deepen JPMorgan's presence in the venture capital space. Designed to streamline fundraising for <a href="https://www.benzinga.com/news/25/05/45298199/vogue-approved-startup-mull-club-recycles-over-1500-pounds-of-plastic-into-designer-homeware-backed-by-fortnum-mason-and-lush">startup</a> founders and strengthen ties with VC firms, the platform was seen as JPMorgan's answer to Silicon Valley Bank's once-dominant position in the startup ecosystem, Fortune reports.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
Capital Connect promised seamless fundraising tools, streamlined investor matchmaking, and integrations with JPMorgan&#8217;s broader banking services. The launch came in October 2022, just two months after the bank <a href="https://www.jpmorgan.com/about-us/corporate-news/2022/jpmorgan-completes-acquisition-of-global-shares">acquired</a> Global Shares, a company offering software for managing employee stock plans, and shortly before it closed its acquisition of data analytics firm Aumni, as confirmed in a statement by <a href="https://www.dlapiper.com/en-us/news/2023/05/dla-piper-advises-aumni-in-its-business-combination-with-jp-morgan">DLA Piper</a> in May 2023.
<h2 class="wp-block-heading">Competitive Pressures and a Shifting Market</h2>
Four sources familiar with the matter confirmed that Capital Connect simply didn't meet expectations, according to Fortune. One of those sources told Fortune that Capital Connect "didn't really reach a state where it had bespoke value to offer all ends of the marketplace."
Despite the platform's ambitious vision, Capital Connect struggled to gain meaningful traction in the market. Though JPMorgan has not officially disclosed the reasons behind its quiet closure, the decision shows that the initiative may have fallen short of delivering the strategic impact originally envisioned. Rather than continue pouring resources into a standalone product, the bank is now redirecting its focus toward deepening its relationships with the venture capital ecosystem through its existing, more established banking channels, according to<a href="https://www.crowdfundinsider.com/2025/05/239293-jpmorgan-discontinues-capital-connect-platform-shifts-focus-to-traditional-banking-relationships/"> Crowdfund Insider</a>.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
Meanwhile, global venture capital was entering a cooling phase.<a href="https://news.crunchbase.com/venture/startup-investment-charts-q1-2025/"> Crunchbase</a> says that in the first quarter of this year, global venture capital funding hit $113 billion, but according to<a href="https://fortune.com/2025/04/01/openai-finalizes-40-billion-funding-at-300-billion-value/"> Fortune</a>, over $40 billion of that came from OpenAI's raise alone.
<h2 class="wp-block-heading">JPMorgan Shifts Strategy While Preserving Startup Ties</h2>
Despite the closure, JPMorgan says its commitment to the innovation economy hasn't wavered. Most of the 200 employees who worked on Capital Connect were reassigned across the firm, especially into JPMorgan's global banking and digital services units, Fortune reports.
Capital Connect's backend is now being repurposed for another project JPMorgan plans to unveil in the coming months, according to Fortune. Global Shares, once part of the Capital Connect bundle, has been rebranded as J.P. Morgan Workplace Solutions and remains active.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
The bank has also bulked up its innovation economy business through other strategic moves. JPMorgan in May 2023 swooped in <a href="https://www.jpmorganchase.com/ir/news/2023/jpmc-acquires-substantial-majority-of-assets-and-assumes-certain-liabilities-of-first-republic-bank">to acquire</a> the bulk of First Republic's assets after the bank became the second-largest U.S. bank failure since 2008, according to <a href="https://www.bloomberg.com/news/articles/2023-05-01/first-republic-ranks-as-second-largest-ever-us-bank-failure">Bloomberg</a>. The Federal Deposit Insurance Corp. <a href="https://www.fdic.gov/resources/resolutions/bank-failures/failed-bank-list/first-republic.html">confirmed</a> in May 2023 that First Republic was closed by California regulators and placed into receivership before JPMorgan was selected as the buyer.
<h2 class="wp-block-heading">A Lesson in Moving Fast and Adapting Faster</h2>
JPMorgan's attempt to become the &#8220;startup banker&#8221; through Capital Connect didn't land, but the bank hasn't slowed down. With over 500 bankers now working in its innovation economy group and nearly 10,000 venture-backed clients, the bank is doubling down on services, not platforms, to build long-term loyalty in the space, according to Fortune.
Capital Connect can be seen as an experiment that proved traditional finance can't always match the speed, expectations, or ethos of startup culture with technology alone.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Capital Connect Crumbles: JPMorgan's $175M Bet On Startup Platform Ends Amidst Venture Capital Market Turmoil

MercadoLibre's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NYSE">MELI</a>) short percent of float has fallen 19.89% since its last report. The company recently reported that it has 715 thousand shares sold short, which is 1.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>MercadoLibre Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747324837_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MercadoLibre has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MercadoLibre's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MercadoLibre's peer group average for short interest as a percentage of float is 10.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MELI

Peering Into MercadoLibre's Recent Short Interest

Truist Securities analyst Korinne Wolfmeyer maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and raises the price target from $364 to $386.

ULTA

Truist Securities Maintains Neutral on Ulta Beauty, Raises Price Target to $386

StepStone Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NYSE">STEP</a>) short percent of float has risen 3.79% since its last report. The company recently reported that it has 2.49 million shares sold short, which is 4.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>StepStone Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747324832_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for StepStone Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing StepStone Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, StepStone Group's peer group average for short interest as a percentage of float is 3.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

STEP

How Is The Market Feeling About StepStone Group?

Looking into the current session, Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares are trading at $403.01, after a 0.89% increase. Moreover, over the past month, the stock increased by 15.54%, but in the past year, decreased by 16.64%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747324829_0.png" alt="Past Year Chart" />

<h3>Adobe P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Adobe has a lower P/E than the aggregate P/E of 96.96 of the Software industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747324829_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

ADBE

A Look Into Adobe Inc's Price Over Earnings

Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.72%. Currently, Watsco has a market capitalization of $19.38 billion. 
Buying $1000 In WSO: If an investor had bought $1000 of WSO stock 20 years ago, it would be worth $10,813.62 today based on a price of $478.40 for WSO at the time of writing.
<h3>Watsco's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747324827_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Watsco Stock In The Last 20 Years

NiSource's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) short percent of float has risen 4.15% since its last report. The company recently reported that it has 11.11 million shares sold short, which is 3.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>NiSource Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747324826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NiSource has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing NiSource's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, NiSource's peer group average for short interest as a percentage of float is 3.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About NiSource?

Health Care

Press Releases

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Coherus BioSciences

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Immunic

Inozyme Pharma

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

OncoCyte

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Senti Biosciences

Instil Bio

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Comments

Elicio Therapeutics

Noticias

Últimas noticias sobre Elicio Therapeutics (NASDAQ:ELTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL